louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06917053: Renal Perfusion and the Development of AKI Following Traumatic Injury
Official title: Renal Perfusion and the Development of AKI Following Traumatic Injury - A Longitudinal Observational Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Traumatic Haemorrhagic Shock
AKI (Acute Kidney Injury) Due to Trauma
AKI - Acute Kidney Injury
Lead sponsor: King's College Hospital NHS Trust
Sponsor class: OTHER
First posted: 2025-04-08
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted to critical care with traumatic haemorrhagic shock who fulfill the inclusion and do no meet any exclusion criteria.

Brief summary: Acute kidney injury (AKI) is a complication of traumatic haemorrhagic shock (THS) and together these conditions increase mortality risk. Although septic shock patients who develop severe AKI are known to develop hypoperfusion of the renal cortex, little is known regarding intra-renal perfusion changes in THS. The aim of the current study is to investigate the effects of THS on renal microcirculatory perfusion.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Within 24 hours of ICU admission following traumatic injury
* Received any blood products during initial resuscitation
* Lactate \> 2 mmol/l at any stage prior to study enrolment

Exclusion Criteria:

* Known intolerance to Sonovue or any other ultrasound contrast agent
* Patients with un-survivable injuries / not expected to survive 24 hours in whom the intent of treatment is palliative
* Known CKD 4 or end stage renal failure
* Pregnancy

Primary outcomes:
measure: Cortical mean transit time (mTT) measured in seconds
timeFrame: Measured at enrollment, +24 hours and + 48 hours
Secondary outcomes:
measure: Cortical perfusion index (PI) measured in arbitrary units
timeFrame: Measured at enrollment, +24 hours and + 48 hours
measure: Cortical wash in rate (WiR) measured in arbitrary units
timeFrame: Measured at enrollment, +24 hours and + 48 hours
measure: Urinary oxygen tension (pO2) across 24 hours study period measured in millimetres of mercury (mmHg)
timeFrame: Across 48 hour study period
Other outcomes:
measure: Perfused vessel density (PVD) measured in millimetres per square millimetre
timeFrame: Measured at enrollment, +24 hours and + 48 hours
measure: Microvascular flow index (MFI) (unitless score from 0 to 3 where 3 is the value see in health)
timeFrame: Measured at enrollment, +24 hours and + 48 hours
measure: Syndecan 1, angiopoietin 1 & 2, Interleukin 6 & 8 (IL-6, IL-8) and tissue necrosis factor (TNF). All measured in nanograms per millilitre (ng/ml)
timeFrame: Measured at enrollment and + 48 hours
Locations:
city: London
country: United Kingdom
facility: King's College Hospital
Study officials:
References:
Clinical trial NCT01915953: A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Monitor NBM200/MP
Official title: A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Monitor NBM200/MP
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Anemia
Keywords: Accurte Hb noninvasive measurement
Lead sponsor: OrSense, Ltd.
Sponsor class: INDUSTRY
First posted: 2013-08-05
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hematology pateints

Brief summary: The purpose of the study is to define the precision, accuracy and variability of the NBM-200 system in non invasive blood Hemoglobin (Hb) measurements relative to the laboratory blood analyzer by comparing two consecutive Hb values obtained by the NBM system to venous values.

Detailed description: Each subject will be placed in a comfortable position in a temperature regulated room. Participants will have two consecutive non invasive (NBM) measurements taken which involves inserting the thumb into a ring shaped sensor. After each non invasive measurement the sensor will be removed. Each measurement takes approximately 85 seconds and involves the finger cuff inflating (to over systolic pressure) and deflating several times in quick successions in order to measure and calculate the Hb values. The two non invasive measurements will be performed using the same finger. After the NBM system testing is complete and recorded, the subject will have a venous (venipuncture) blood sample collected in order to provide two blood tests performed on two different models of routine automated complete blood count or Hb blood analyzers.

Eligibility criteria: Inclusion Criteria:

* Participants aged 18 years and over

Exclusion Criteria:

* Participants under the age of 18 years
* Patients with significant deformity, degenerative changes or oedema of the fingers or hand
* Patients with localized infection, ulceration or skin breaks involving the fingers
* Patients with vascular disease or Raynaud's phenomenon affecting the fingers (vasospasm)
* Participants who are unable to give informed written consent

Primary outcomes:
measure: compre the Hb values from the NBM200 series gainst the Hb from the lab blood analyser on Hematology pateints
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Beer Yaacov
country: Israel
facility: Assaf Harofeh Medical Center
Study officials:
affiliation: Assaf-Harofeh Medical Center
name: Abraham Korenberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01419353: Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol
Official title: Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility
Keywords: Infertility, IVF, Estrogen
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2011-08-18
Enrollment: 63
Sex: FEMALE
Maximum age (years): 38
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if pretreatment with Estrogen can assist in the planning and programming of In Vitro Fertilization treatments.

Detailed description: A randomised controlled trial in which study group will be given estrogen derivative before ovarian stimulation in GnRH antagonist protocol and compared to the classical GnRH agonist protocol.Estrogen will be given P.O , "PROGYNOVA' , in a dose of 2 mg /d, starting day 2 of menses and until first Monday to follow. Main outcome measure will be ability to control the ovum pickup day, calculated as a rate of ideal pickups divided by the entire pickup number. All women enrolled will be under 38 years of age, with a clear indication for IVF other than ovulatory dysfunction. women with past 4 treatment failures will be excluded as well as cases in which sperm achieved in surgical methods.

Eligibility criteria: Inclusion Criteria:

* IVF treatment in the following indications: Male, Mechanical, Unexplained
* Age\<38 years
* Treatment Cycle number 1-4

Exclusion Criteria:

* Ovulatory disorder as an indication for IVF
* Repeated failure in previous IVF treatments (\> than 4 cycles)
* Sperm used for treatment was retrieved by surgical procedure

Primary outcomes:
measure: ovum pickup rate that took place between Sunday to Thursday without a compromise
timeFrame: a year
Secondary outcomes:
measure: pregnancy rate
timeFrame: a year
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
affiliation: Meir Medical Center
name: Adrian Shulman, MD
role: STUDY_CHAIR
References:
citation: Hershko Klement A, Berkovitz A, Wiser A, Gonen O, Amichay K, Cohen I, Ghetler Y, Shulman A. GnRH-antagonist programming versus GnRH agonist protocol: a randomized trial. Eur J Obstet Gynecol Reprod Biol. 2015 Feb;185:170-3. doi: 10.1016/j.ejogrb.2014.12.021. Epub 2014 Dec 29.
Clinical trial NCT03053453: Evaluation of Patient Reported Outcomes (PRO) After Total Knee Arthroplasty (TKA) Under Spinal Anesthesia
Official title: Evaluation of the Patient Reported Outcomes After Sensor-guided Total Knee Arthroplasty Under Spinal Anesthesia With Limited Motor-block.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Knee Injuries
Keywords: Total Knee Replacement Arthroplasty
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2017-02-15
Enrollment: 52
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a randomized prospective study looking at the impact sensor guidance has on the outcome of patients and comparing to that of patients with a standard technique.
Primary purpose: TREATMENT

Brief summary: The purpose of this study will be to evaluate and compare patients undergoing total knee arthroplasty (TKA) with sensor guidance versus that of a standard technique. Each patient will be assessed for the difference between passive, soft tissue controlled, pressure balance and muscle activated pressure balance.


Eligibility criteria: Inclusion Criteria:

* Patients will be screened for eligibility based on whether they have chronic knee pain as a result of an arthritis-related condition.
* Patient with chronic knee pain who is indicated for total hip or knee replacement surgery
* Patient is at least 50 years of age
* Patient is willing to participate in pre- and postoperative surveys

Exclusion Criteria:

* Failure to complete pre-operative surveys.
* Revision Total Knee Arthroplasty
* Prior ipsilateral knee surgery such as ligament reconstruction or osteotomy
* Contralateral Total Knee Arthroplasty
* Prior tibial plateau fracture
* Ligamentous Insufficiency
* History of fibromyalgia, chronic fatigue syndrome

Primary outcomes:
measure: Knee Society Score (KSS)
timeFrame: Month 12 Post-Surgery
measure: Knee Injury and Osteoarthritis Outcome Score (KOOS)
timeFrame: Month 12 Post-Surgery
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU Langone Health
name: Arthur Hertling, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01434953: Prehypertension Labeling
Official title: Diagnostic Labeling: Effect on White Coat Hypertension
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Prehypertension
Keywords: Prehypertension
Blood pressure screening
White coat effect
Lead sponsor: Columbia University
Sponsor class: OTHER
First posted: 2011-09-15
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The purpose of this study is to find out whether labeling adults with prehypertension has negative effects on clinic blood pressure and quality of life 3 months after diagnosis.

Detailed description: Previous research has shown that a diagnosis of hypertension is associated with subsequent increases in resting blood pressure, and there is preliminary evidence of a cross-sectional association between hypertension labeling and the white coat effect. The white coat effect may be particularly problematic in prehypertensives, because a small elevation in clinic blood pressure could result in crossing the diagnostic cutoff for hypertension, potentially leading to misdiagnosis and unnecessary treatment. This study will examine effects of prehypertension labeling on clinic and ambulatory blood pressure, and will examine potential psychological mediators of these associations.

Eligibility criteria: Inclusion Criteria:

* at least 18 years
* average screening systolic blood pressure of 120-139 mmHg OR diastolic blood pressure of 80-89 mmHg
* average screening systolic blood pressure below 140 mmHg AND diastolic blood pressure below 90 mmHg
* able to read and write in English

Exclusion Criteria:

* past diagnosis of hypertension, prehypertension, or high blood pressure
* current or past use of antihypertensive medications
* diabetes
* renal disease
* cardiovascular disease
* current participation in another hypertension-related clinical trial

Primary outcomes:
measure: Change in blood pressure
timeFrame: Baseline, 3 months
Secondary outcomes:
measure: Change in health-related quality of life (SF-12 questionnaires)
timeFrame: Baseline, 3 months
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Matthew Burg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02768753: Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy
Official title: Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thyroid Papillary Carcinoma
Thyroidectomy
Keywords: Robotic thyroidectomy
Robotic central neck dissection
Axillary bilateral-breast approach
Bilateral axillo-breast approach
Lead sponsor: Jinan Military General Hospital
Sponsor class: OTHER
First posted: 2016-05-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the therapeutic effects between the axillary bilateral-breast approach (ABBA) and bilateral axillo-breast approach (BABA) for robotic thyroidectomy.To explore the efficacy, safety, cosmetic results and clinical value by the two approaches.

Detailed description: Although several reports on operative outcomes of the robotic technique have appeared, no prospective trials comparing the clinical results of between the axillary bilateral-breast approach (ABBA) and bilateral axillo-breast approach (BABA) for robotic thyroidectomy have been described. The investigators therefore designed a prospective trial comparing outcomes, including surgical outcomes and patient satisfaction, between patients undergoing robotic and conventional open thyroidectomy.

Eligibility criteria: Inclusion Criteria:

1. the initial surgery
2. preoperative needle aspiration biopsy of thyroid cancer, and the diameter of no more than 1cm, no lateral neck lymph node metastasis
3. the tumor is confined to the thyroid membrane, not invading trachea and recurrent laryngeal nerve
4. intraoperative frozen section diagnosis of thyroid cancer
5. the patient informed consent.

Exclusion Criteria:

1. high-frequency ultrasound preoperative tumor diameter greater than 1cm, or lateral neck lymph node metastasis in patients
2. there had been a history of thyroid surgery or neck radiation therapy
3. pregnant or lactating women
4. with severe Hashimoto's thyroiditis, thyroid volume greater than II °
5. coagulation disorders, hyperthyroidism or hypothyroidism patients
6. sternal goiter.

Primary outcomes:
measure: Change of VAS Pain Scores for the First 24 Hours
timeFrame: The pain scores of 2pm, 10pm and 6am on the first day after operation were evaluated.The mean values were calculated and recorded.
measure: Cosmetic Outcomes
timeFrame: 3 months after surgery
Secondary outcomes:
measure: Subjective Voice
timeFrame: After operation 8 a.m. on the 7th day
measure: Swallowing Evaluation
timeFrame: 8 a.m. on the 3rd day after operation
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of thyroid and breast surgery, General Hospital of Jinan Military Area
state: Shandong
Study officials:
References:
Clinical trial NCT05583253: Visual Outcome of Vitrectomy After Refractive Surgery
Official title: Visual Outcome of Small Gauge Pars-plana Vitrectomy for Retinal Detachment With Previous Refractive Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Retinal Detachment
Refractive Errors
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2022-10-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Results of retinal detachment surgery may be affected in cases with history of previous intraocular surgery.

Detailed description: Pars-plana vitrectomy for management of retinal detachment has favorable visual outcome with early intervention and development of small gauge instruments, cases with previous refractive surgery may be affected by other factors that may change the final visual outcome.

In this study, we aim to analyze the effect of refractive surgeries on the final visual outcome after vitrectomy for the management of retinal detachment.

Eligibility criteria: Inclusion Criteria:

* cases diagnosed with primary retinal detachment and prepared for pars-plana vitrectomy.
* cases with previous history for refractive surgery were enrolled in refractive surgery group.

Exclusion Criteria:

* cases with corneal diseases or trauma that may affect the final visual outcome.
* cases with other retinal diseases that may affect the final visual outcome as age related macular degenerations and diabetic eye disease.

Primary outcomes:
measure: Visual acuity
timeFrame: Baseline and 6 months after surgery.
Secondary outcomes:
measure: Corneal endothelial cells count
timeFrame: Baseline and 6 months after surgery.
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Benha University
state: QA
Study officials:
affiliation: Benha University
name: Marwa A Abdelshafy, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01033253: Multi-media Obesity Prevention Program for Adolescents
Official title: Multi-media Obesity Prevention Program for Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Physical Activity
Nutrition
Obesity Prevention
Lead sponsor: Pro-Change Behavior Systems
Sponsor class: OTHER
First posted: 2009-12-16
Enrollment: 1800
Sex: ALL
Minimum age (years): 13
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of this project was to evaluate a population-based, computerized tailored intervention that addresses recommended guidelines for three target behaviors related to obesity risk: physical activity (at least 60 minutes on at least 5 days per week), fruit and vegetable consumption (at least 5 servings of fruits and vegetables each day), and limited TV viewing (2 hours or less of TV each day).


Eligibility criteria: Inclusion Criteria:

* English speaking
* In the 9th, 10th, or 11th grade at baseline

Exclusion Criteria:

-

Primary outcomes:
measure: The number of days per week for which students got at least 60 minutes of physical activity
timeFrame: 2, 6, and 12 months
measure: The number of servings of fruits and vegetables consumed each day
timeFrame: 2, 6, and 12 months
measure: The number of hours of TV watch each day, including time spent watching TV, videotapes, and DVD's
timeFrame: 2, 6, and 12 months
Secondary outcomes:
measure: Stage of change for readiness to do at least 60 minutes of physical activity on at least 5 days of the week
timeFrame: 2, 6, and 12 months
measure: Stage of change for readiness to eat at least five servings of fruits and vegetables each day.
timeFrame: 2, 6, and 12 months
measure: Stage of change for readiness to watch two hours or less of TV each day.
timeFrame: 2, 6, and 12 months
Other outcomes:
Locations:
city: Kingston
country: United States
facility: Pro-Change Behavior Systems, Inc.
state: Rhode Island
Study officials:
affiliation: Pro-Change Behavior Systems
name: Leanne Mauriello, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Driskell MM, Dyment S, Mauriello L, Castle P, Sherman K. Relationships among multiple behaviors for childhood and adolescent obesity prevention. Prev Med. 2008 Mar;46(3):209-15. doi: 10.1016/j.ypmed.2007.07.028. Epub 2007 Aug 1.
citation: Mauriello LM, Driskell MM, Sherman KJ, Johnson SS, Prochaska JM, Prochaska JO. Acceptability of a school-based intervention for the prevention of adolescent obesity. J Sch Nurs. 2006 Oct;22(5):269-77. doi: 10.1177/10598405060220050501.
citation: Mauriello LM, Sherman KJ, Driskell MM, Prochaska JM. Using interactive behavior change technology to intervene on physical activity and nutrition with adolescents. Adolesc Med State Art Rev. 2007 Aug;18(2):383-99, xiii.
Clinical trial NCT01917253: Standard Length Catheters vs Long Catheters in Peripheral Vein Cannulation.
Official title: Standard Length Catheters vs Long Catheters in Peripheral Vein Cannulation. A Randomized Controlled Clinical Trial to Test the Complications.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Complications
Keywords: infiltration, phlebitis, occlusion, thrombosis
Lead sponsor: ASL TO2 Torino
Sponsor class: OTHER
First posted: 2013-08-06
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The Long and Short is a prospective, randomized, controlled, open label trial to test the complications of different device for peripheral vein cannulation, standard length (about 5 cm in length) and long catheter (about 12 cm in length), inserted with Seldinger technique.

Detailed description: The trial will compare the main complications: infiltration rate, phlebitis rate, occlusion and/or dislocation rate, thrombosis rate, number of percutaneous sticks, successful cannulation.

Will be made for a cost analysis.

Eligibility criteria: Inclusion Criteria:

* adult patients
* infusional therapy more than 72 hours

Exclusion Criteria:

* need for central venous catheter

Primary outcomes:
measure: complications rate
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Torino
country: Italy
facility: MECAU-Maria Vittoria Hospital
Study officials:
affiliation: ASLTO2- MECAU- Maria Vittoria Hospital
name: Piero Riva, MD
role: PRINCIPAL_INVESTIGATOR
References: